Cardiovascular eff ects of psychotropic drugs
https://doi.org/10.30629/0023-2149-2023-101-9-10-467-473
Abstract
Research over the past decade indicates that some psychotropic drugs increase the risk of developing arrhythmias and sudden cardiac death. Many antidepressants and antipsychotic drugs have arrhythmogenic potential and are associated with QT interval prolongation and development of ventricular arrhythmia of the “torsades de pointes” type, while some psychotropic drugs are associated with changes in ECG phenotype of Brugada syndrome and development of polymorphic ventricular arrhythmias.
About the Author
Ya. Т. Vardanyan
Lomonosov Moscow State University
Russian Federation
Russian Federation
Yana Т. Vardanyan
119991, Moscow
References
1. Buckley N.A., Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Safety. 2000;23(3):215–28. DOI: 10.2165/00002018-200023030-00004
2. Herxheimer A., Healy D. Arrhythmias and sudden death in patients taking antipsychotic drugs. BMJ. 2002;325(7375):1253–1254. DOI: 10.1136/BMJ.325.7375.1253
3. Thioridazine hydrochloride (mellaril): its effect on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities. PubMed. URL: https://pubmed.ncbi.nlm.nih.gov/14045347/ (accessed Nov. 30, 2021)
4. Yuhas J. et al. Patients’ attitudes and perceptions of implantable cardioverter-defi brillators: potential barriers to appropriate primary prophylaxis. Pacing Clin. Electrophysiol. 2012;35(10):1179–1187. DOI: 10.1111/J.1540-8159.2012.03497.X
5. Sicouri S., Antzelevitch C. Clinical Reviews: Drugs and Devices Drug-induced Long QT Syndrome and Torsade de Pointes by Antidepressant and Antipsychotic Agents Mechanisms Underlying the Actions of Antidepressant and Antipsychotic Drugs That Cause Sudden Cardiac Arrest. Cit. Arrhythmia Electrophysiol. Rev. 2018;7(3):199–209. DOI: 10.15420/aer.2018.29.2
6. Brugada P., Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome: A multicenter report. J. Am. Coll. Cardiol. 1992;20(6):1391–1396. DOI: 10.1016/0735-1097(92)90253-J
7. Wilde A.A.M. et al. Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation. 2002;106(19):2514–2519. DOI: 10.1161/01.CIR.0000034169.45752.4A
8. Funk M.C. et al. QTc Prolongation and Psychotropic Medications. Am. J. Psychiatry. 2020;177(3):273–274. DOI: 10.1176/APPI.AJP.2019.1760501
9. Teply R.M., Packard K.A., White N.D., Hilleman D.E., DiNicolantonio J.J. Treatment of Depression in Patients with Concomitant Cardiac Disease. Prog. Cardiovasc. Dis. 2016:58(5):514–528. DOI: 10.1016/J.PCAD.2015.11.003
10. Gibbons R.D., Hur K., Bhaumik D.K., Mann J.J. The relationship between antidepressant medication use and rate of suicide. Arch. Gen. Psychiatry. 2005:62(2):165–172. DOI: 10.1001/archpsyc.62.2.165
11. Carvalho A.F., Sharma M.S., Brunoni A.R., Vieta E., Fava G.A. The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychother. Psychosom. 2016:85(5):270–288. DOI: 10.1159/000447034
12. Bolognesi R., Tsialtas D., Vasini P., Conti M., Manca C. Abnormal ventricular repolarization mimicking myocardial infarction after heterocyclic antidepressant overdose. Am. J. Cardiol. 1997:79(2):242– 245. DOI: 10.1016/S0002-9149(96)00727-8
13. Darbar D., Yang T., Churchwell K., Wilde A.A.M., Roden D.M. Un masking of brugada syndrome by lithium. Circulation. 2005:112(11):1527–1531. DOI: 10.1161/CIRCULATIONAHA.105.548487
14. Danielsson B., Collin J., Jonasdottir Bergman G., Borg N., Salmi P., Fastbom J. Antidepressants and antipsychotics classifi ed with torsades de pointes arrhythmia risk and mortality in older adults — a Swedish nationwide study. Br. J. Clin. Pharmacol. 2016:81(4):773. DOI: 10.1111/BCP.12829
15. O’Regan C., Kenny R.A., Cronin H., Finucane C., Kearney P.M. Antidepressants strongly infl uence the relationship between depression and heart rate variability: fi ndings from The Irish Longitudinal Study on Ageing (TILDA). Psychol. Med. 2015:45(3):623–636. DOI: 10.1017/S0033291714001767
16. Kemp A.H. et al. Effects of depression, anxiety, comorbidity, and antidepressants on resting-state heart rate and its variability: an ELSA-Brasil cohort baseline study. Am. J. Psychiatry. 2014:171(12):1328–1334. DOI: 10.1176/APPI.AJP.2014.13121605
17. Kemp A.H. et al. Effects of depression, anxiety, comorbidity, and antidepressants on resting-state heart rate and its variability: an ELSA-Brasil cohort baseline study. Am. J. Psychiatry. 2014:171(12):1328–1334. DOI: 10.1176/APPI.AJP.2014.13121605
18. Taylor C.B. Depression, heart rate related variables and cardiovascular disease. Int. J. Psychophysiol. 2010:78(1):80–88. DOI: 10.1016/J.IJPSYCHO.2010.04.006
19. Behlke L.M., Lenze E.J., Carney R.M. The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases. CNS Drugs. 2020:34(11):1133– 1147. DOI: 10.1007/S40263-020-00763-Z
20. Upward J., Edwards J., Goldie A., and Waller D. Comparative effects of fl uoxetine and amitriptyline on cardiac function. Br. J. Clin. Pharmacol. 1988:26(4):399–402. DOI: 10.1111/J.1365-2125.1988.TB03397.X
21. Funk K.A., Bostwick J.R. A comparison of the risk of QT prolongation among SSRIs. Ann. Pharmacother. 2013:47(10):1330–1341. DOI: 10.1177/1060028013501994
22. Sicouri S., Antzelevitch C. Mechanisms Underlying the Actions of Antidepressant and Antipsychotic Drugs That Cause Sudden Cardiac Arrest. Arrhythmia Electrophysiol. Rev. 2018:7(3):199–209. DOI: 10.15420/AER.2018.29.2
23. Cubeddu L. Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias. Curr. Cardiol. Rev. 2016:12(2):141–154. DOI: 10.2174/1573403X12666160301120217
24. Seo J.S. et al. Korean Medication Algorithm for Depressive Disorder 2021, Fourth Revision: An Executive Summary. Clin. Psychopharmacol. Neurosci. 2021:19(4):751–772. DOI: 10.9758/cpn.2021.19.4.751
25. Darowski A., Chambers S.A.C.F., Chambers D.J., Antidepressants and falls in the elderly. Drugs Aging. 2009:26(5):381–394. DOI: 10.2165/00002512-200926050-00002
26. Cherin P., Colvez A., De Periere G.D., Sereni D. Risk of syncope in the elderly and consumption of drugs: a case-control study. J. Clin. Epidemiol. 1997:50(3):313–320. DOI: 10.1016/S0895-4356(96)00385-X
27. Pehrson A.L. et al. Treatment of cognitive dysfunction in major depressive disorder - A review of the preclinical evidence for effi cacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine. Eur. J. Pharmacol. 2015:753:19–31. DOI: 10.1016/J.EJPHAR.2014.07.044
28. Jasiak N.M., Bostwick J.R. Risk of QT/QTc prolongation among newer non-SSRI antidepressants.Ann. Pharmacother. 2014:48(12):1620– 1628. DOI: 10.1177/1060028014550645
29. Whiskey E. Taylor D. A review of the adverse eff ects and safety of noradrenergic antidepressants. J. Psychopharmacol. 2013:27(8):732– 739. DOI: 10.1177/0269881113492027
30. Johnson E.M. et al. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am. J. Geriatr. Psychiatry. 2006:14(9):796–802. DOI: 10.1097/01.JGP.0000204328.50105.B3
31. Thase M.E., Tran P.V., Wiltse C., Pangallo B.A., Mallinckrodt C., Detke M.J. Cardiovascular profi le of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J. Clin. Psychopharmacol. 2005:25(2):132–140. DOI: 10.1097/01.JCP.0000155815.44338.95
32. Asnis G.M., Henderson M.A. Levomilnacipran for the treatment of major depressive disorder: a review. Neuropsychiatr. Dis. Treat. 2015:11:125–135. DOI: 10.2147/NDT.S54710
33. Goldgran-Toledano D., Sideris G., Kevorkian J.-P. Overdose of cyclic antidepressants and the Brugada syndrome. N. Engl. J. Med. 2002:346(20):1591–1592. DOI: 10.1056/NEJM200205163462020
34. De La Torre B.R. et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther. Drug Monit. 2001:23(4):435–440. DOI: 10.1097/00007691-200108000-00019
35. Glassman A.H. Cardiovascular effects of tricyclic antidepressants. Annu. Rev. Med. 1984:35:503–511. DOI: 10.1146/ANNUREV.ME.35.020184.002443
36. Beach S.R. et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J. Clin. Psychiatry. 2014:75(5):e441–449. DOI: 10.4088/JCP.13R08672
37. Vieweg W.V.R., Wood M.A. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics. 2004:45(5):371–377. DOI: 10.1176/APPI.PSY.45.5.371
38. Wenzel-Seifert K., Wittmann M., Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch. Arztebl. Int. 2011:108(41):687–693. DOI: 10.3238/ARZTEBL.2011.0687
39. Nelson J.C., Pritchett Y.L., Martynov O., Yu J.Y., Mallinckrodt C.H., Detke M.J. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Prim. Care Companion J. Clin. Psychiatry. 2006:8(4):212–219. DOI: 10.4088/PCC.V08N0404
40. Alampay M.M., Haigney M.C., Flanagan M.C., Perito R.M., Love K.M., Grammer G.G., Transcranial magnetic stimulation as an antidepressant alternative in a patient with Brugada syndrome and recurrent syncope. Mayo Clin. Proc. 2014:89(11):1584–1587. DOI: 10.1016/J.MAYOCP.2014.08.010
41. Rouleau F. et al. Transient ST segment elevation in right precordial leads induced by psychotropic drugs: relationship to the Brugada syndrome. J. Cardiovasc. Electrophysiol. 2001:12(1):61–65. DOI: 10.1046/J.1540-8167.2001.00061.X
42. Chaw B.J.W., Gallab M., Birnie D. Brugada syndrome precipitated by a tricyclic antidepressant. Heart. 2005:91(5):651. DOI: 10.1136/HRT.2004.049593
43. Babaliaros V.C., Hurst J.W. Tricyclic antidepressants and the Brugada syndrome: an example of Brugada waves appearing after the administration of desipramine. Clin. Cardiol. 2002:25(8):395–398. DOI: 10.1002/CLC.4950250809
44. Tada H., Sticherling C., Oral H., Morady F. Brugada syndrome mimicked by tricyclic antidepressant overdose. J. Cardiovasc. Electrophysiol. 2001;12(2):275. DOI: 10.1046/J.1540-8167.2001.00275.X
45. Bigwood B., Galler D., Amir N., Smith W. Brugada syndrome following tricyclic antidepressant overdose. Anaesth. Intensive Care. 2005:33(2):266–270. DOI: 10.1177/0310057X0503300219
46. Sicouri S., Antzelevitch C. Mechanisms Underlying the Actions of Antidepressant and Antipsychotic Drugs That Cause Sudden Cardiac Arrest. Arrhythmia Electrophysiol. Rev. 2018:7(3):199–209. DOI: 10.15420/AER.2018.29.2
47. Carrà G. et al. First-generation antipsychotics and QTc: any role for mediating variables? Hum. Psychopharmacol. 2016:31(4):313–318. DOI: 10.1002/HUP.2540
48. Wu C.S., Tsai Y.T., Tsai H.J. Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study. J. Am. Heart Assoc. 2015:4(2). DOI: 10.1161/JAHA.114.001568
49. Beach S.R., Celano C.M., Noseworthy P.A., Januzzi J.L., Huffman J.C. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013:54(1):1–13. DOI: 10.1016/J.PSYM.2012.11.001
50. Harrigan E.P. et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J. Clin. Psychopharmacol. 2004:24(1):62–69. DOI: 10.1097/01.JCP.0000104913.75206.62
51. Chong S.A., Mythily A., Lum A., Goh H.Y., Chan Y.H. Prolonged QTc intervals in medicated patients with schizophrenia. Hum. Psychopharmacol. 2003:18(8):647–649. DOI: 10.1002/HUP.540
52. Glassman A.H., Bigger J. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am. J. Psychiatry. 2001:158(11):1774–1782. DOI: 10.1176/APPI.AJP.158.11.1774
53. Thomas D. et al. The antipsychotic drug chlorpromazine inhibits HERG potassium channels. Br. J. Pharmacol. 2003:139(3):567–574. DOI: 10.1038/SJ.BJP.0705283
54. Zeuli J.D., Wilson J.W., Estes L.L. Effect of combined fl uoroquinolone and azole use on QT prolongation in hematology patients. Antimicrob. Agents Chemother. 2013:57(3):1121–1127. DOI: 10.1128/AAC.00958-12
55. Leucht S. et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet (London, England). 2013:382(9896):951–962. DOI: 10.1016/S0140-6736(13)60733-3
56. Beach S.R. et al. QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update. Psychosomatics. 2018:59(2):105–122. DOI: 10.1016/J.PSYM.2017.10.009
57. Spyker D.A., Voloshko P., Heyman E.R., Cassella J.V. Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects. J. Clin. Pharmacol. 2014:54(6):665–674. DOI: 10.1002/JCPH.257
58. Cassella J.V., Spyker D.A., Yeung P.P. A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 2015:53(11):963–971. DOI: 10.5414/CP202457
59. Tracz K., Owczuk R. Small doses of droperidol do not present relevant torsadogenic actions: a double-blind, ondansetron-controlled study. Br. J. Clin. Pharmacol. 2015:79(4):669–676. DOI: 10.1111/BCP.12527
60. Polcwiartek C. et al. The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach. Psychopharmacology (Berl). 2015:232(18):3297– 3308. DOI: 10.1007/S00213-015-4024-9
61. Goff D.C. et al. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. J. Clin. Psychopharmacol. 2013:33(4):485–490. DOI: 10.1097/JCP.0B013E3182977308
62. Camm A.J. et al. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data. CNS Drugs. 2012:26(4):351– 365. DOI: 10.2165/11599010-000000000-00000
63. Edinoff A. et al. Cariprazine to Treat Schizophrenia and Bipolar Disorder in Adults. Psychopharmacol. Bull. 2020:50(4):83–117. URL: https://pubmed.ncbi.nlm.nih.gov/33012874/. Accessed: Nov. 30, 2021.
Review
For citations:
Vardanyan Ya.Т. Cardiovascular eff ects of psychotropic drugs. Clinical Medicine (Russian Journal). 2023;101(9-10):467-473. (In Russ.) https://doi.org/10.30629/0023-2149-2023-101-9-10-467-473
Views:
582
Email this article 